April Franks

OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models

Andrew J. Garton, Andrew P. Crew, Maryland Franklin et al. · Cancer Research · 2006 · 80 citations · Full text

Mouse Xenograft Models, Antitumor Activity, Chemoprevention Strategy +18

A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL.

Tanguy Y. Seiwert, Jared Weiss, Shrujal S. Baxi et al. · Journal of Clinical Oncology · 2016 · 32 citations

Immunology, Immune Regulation, Immunoediting +24

LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN

Jonathan W. Goldman, Marina Chiara Garassino, Yuanbin Chen et al. · Annals of Oncology · 2020 · 32 citations · Full text

Hematological Malignancy, Tumor Biology, Lba86 Durvalumab +11

Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle

Robert L. Ferris, C. Even, Robert Haddad et al. · Journal for ImmunoTherapy of Cancer · 2015 · 22 citations · Full text

Squamous Cell Carcinoma, Cancer Management, Immunology +18

Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation

Sophie Wildsmith, Jiabu Ye, April Franks et al. · Cancer Research Communications · 2022 · 11 citations · Full text